Cannabidiol transdermal patch - Greene Street Pharmaceuticals
Alternative Names: CBD-Cubed™ - Greene Street PharmaceuticalsLatest Information Update: 28 Jul 2024
At a glance
- Originator Green Street Pharmaceuticals
- Developer Greene Street Pharmaceuticals
- Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Resorcinols; Skin disorder therapies; Small molecules
- Mechanism of Action 5-HT1 serotonin receptor modulators; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Transient receptor potential channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for research development in Pain in USA (Transdermal, Patch)
- 09 Jun 2020 VerdePharmHealth entered into national group purchasing agreement with Greene Street Pharmaceuticals for Cannabidiol transdermal patch
- 09 Jun 2020 Early research in Pain in USA (Transdermal)